Former Aventis Exec Hofstaetter Finds A New Home At Wyeth
This article was originally published in The Pink Sheet Daily
Thomas Hofstaetter is responsible for business and corporate development as a senior VP, reporting to Wyeth CEO Robert Essner and Pharmaceuticals President Bernard Poussot.
You may also be interested in...
Thomas Hofstaetter was to be one of 10 former Aventis employees to join the merged board's management committee. Sanofi-Aventis says it will still meet its Jan. 1 deadline for having a new operational structure in place.
Sanofi's Tim Rothwell will continue to serve as U.S. CEO, while Aventis' Soriot will head U.S. commercial operations. French market regulator extends closing date of merger to July 30, citing extra time needed for FTC review.
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.